AzTrials
AzTrials

CarcinomaPhase 1/2NCT03611556

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

A Phase 1/2 study testing Oleclumab, Durvalumab and Gemcitabine in people with Carcinoma and Metastatic Pancreatic Adenocarcinoma, run by MedImmune LLC at 27 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer. Read more about this study

Who is it for?
Ages 18 to 101 years
What is being tested?
Oleclumab, Durvalumab and Gemcitabine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
213 participants
Where
27 sitesin 4 countries
Study dates
21 Jun 2018to 22 Jul 2022
Phase
Phase 1/2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 101 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age >= 18
  • Written and signed informed consent must be obtained
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Weight >= 35 kg
  • Participants must have histologically or cytologically, confirmed pancreatic adenocarcinoma:
  • Cohort A: Participants with previously untreated metastatic pancreatic adenocarcinoma (1L metastatic disease) not previously treated with systemic therapies Cohort B: Participants with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, oxaliplatin) 2L metastatic disease
  • Participants must have at least 1 measurable lesion according to RECIST v1.1
  • All Participants must consent to providing archival tumor specimens.

Who cannot join

  • Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.
  • Prior receipt of any immune-related therapy
  • Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
  • Participants with a history of venous thrombosis within the past 3 months
  • Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 3 months prior to start of treatment
  • Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
Show all 9Show fewer
  • Other invasive malignancy within 2 years
  • Any history of leptomeningeal disease or cord compression
  • Current or prior use of immunosuppressive medication within 14 days prior to the first dose.

Trial locations and contacts

27 sites in 4 countries.

27 sites in 4 countries

United States18 sites
  • Research Site

    Ann Arbor, Michigan, 48109

  • Research Site

    Atlanta, Georgia, 30322

  • Research Site

    Aurora, Colorado, 80045

  • Research Site

    Boston, Massachusetts, 02114

  • Research Site

    Boston, Massachusetts, 02215

  • Research Site

    Buffalo, New York, 14263

  • Research Site

    Charlottesville, Virginia, 22908

  • Research Site

    Cincinnati, Ohio, 45219

  • Research Site

    Columbus, Ohio, 43210

  • Research Site

    Dallas, Texas, 75235

  • Research Site

    Durham, North Carolina, 27710

  • Research Site

    Fort Myers, Florida, 33901

  • Research Site

    Houston, Texas, 77030

  • Research Site

    La Jolla, California, 92093

  • Research Site

    Madison, Wisconsin, 53705

  • Research Site

    Nashville, Tennessee, 37203

  • Research Site

    Philadelphia, Pennsylvania, 19111

  • Research Site

    Seattle, Washington, 98109

Other trials in United States

Australia4 sites
  • Research Site

    Blacktown, 2148

  • Research Site

    Clayton, 3168

  • Research Site

    Heidelberg, 3084

  • Research Site

    St Leonards, 2065

Other trials in Australia

Spain4 sites
  • Research Site

    Barcelona, 08035

  • Research Site

    Fuenlabrada, 28942

  • Research Site

    Oviedo, 33011

  • Research Site

    Pamplona, 31008

Other trials in Spain

Norway1 site
  • Research Site

    Oslo, N-0379

Other trials in Norway

About this study

Official title: A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Read the detailed description

This is a Phase 1b/2, multicenter, open-label, dose-escalation, and dose-expansion study to assess the safety, preliminary antitumor activity, immunogenicity, and pharmacokinetics (PK) of oleclumab with or without durvalumab in combination with chemotherapy administered in participants with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants with previously untreated metastatic PDAC (first-line [1L] metastatic PDAC) will be enrolled in Cohort A. Participants with metastatic PDAC previously treated with gemcitabine-based chemotherapy (without exposure to 5-fluorouracil [5-FU], capecitabine, or oxaliplatin; second-line [2L] metastatic PDAC) will be enrolled in Cohort B. The study consists of 2 parts, dose escalation (Part 1) and dose expansion (Part 2).

Keywords
MEDI9447, oleclumab, immunotherapy, pancreatic cancer, durvalumab
Medical subject headings
Carcinoma, Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OleclumabDrug

    Also called MEDI9447

    Participants will receive IV infusion of oleclumab as stated in arm description.

  • DurvalumabDrug

    Also called MEDI4736

    Participants will receive IV infusion of durvalumab as stated in arm description.

  • GemcitabineDrug

    Participants will receive IV infusion of gemcitabine as stated in arm description.

  • Nab-paclitaxelDrug

    Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

  • OxaliplatinDrug

    Also called Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)

    Participants will receive IV infusion of oxaliplatin as stated in arm description.

  • Folinic acidDrug

    Also called Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)

    Participants will receive IV infusion of folinic acid as stated in arm description.

  • 5-FUDrug

    Also called Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)

    Participants will receive IV infusion of 5-FU as stated in arm description.

Study groups in NCT03611556
Study groupRoleWhat they receive
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + nab-paclitaxelExperimentalParticipants with 1L metastatic disease will receive intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Oleclumab; Drug: Durvalumab; Drug: Gemcitabine; Drug: Nab-paclitaxel
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxelExperimentalParticipants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Oleclumab; Drug: Durvalumab; Drug: Gemcitabine; Drug: Nab-paclitaxel
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXExperimentalParticipants with 2L metastatic disease will receive IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m^2 IV; folinic acid 400 mg/m^2 IV; 5-FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Oleclumab; Drug: Durvalumab; Drug: Oxaliplatin; Drug: Folinic acid; Drug: 5-FU
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXExperimentalParticipants with 2L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m^2 IV; folinic acid 400 mg/m^2 IV; 5-FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Oleclumab; Drug: Durvalumab; Drug: Oxaliplatin; Drug: Folinic acid; Drug: 5-FU
Dose-expansion, Gemcitabine + nab-paclitaxelActive comparatorParticipants with 1L metastatic disease will receive IV infusions of chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Gemcitabine; Drug: Nab-paclitaxel
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + nab-paclitaxelExperimentalParticipants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Oleclumab; Drug: Gemcitabine; Drug: Nab-paclitaxel
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxelExperimentalParticipants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Receives: Drug: Oleclumab; Drug: Durvalumab; Drug: Gemcitabine; Drug: Nab-paclitaxel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Measured: Day 1 through 65.7 weeks (maximum observed duration)

  2. Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase

    DLT: Any study drug related Grade (G)3 or higher toxicity including: any G4 immune-mediated AEs, >=G3 colitis/pneumonitis/interstitial lung disease (ILD), >=G3 nausea/vomiting/diarrhea that does not resolve to G2 or less within 3 days of maximal supportive care (MSC), G2 pneumonitis/ILD that does not resolve within 7 days of initiation of MSC, G4 anemia, G3 anemia with clinical sequelae/requires >2 units of red blood cells transfusion, G4 thrombocytopenia/neutropenia >=7 days, G3/4 thrombocytopenia with >=G3 hemorrhage, G4 febrile neutropenia (FN), G3 FN lasting >=5 days while receiving MSC, isolated G3 liver transaminase elevation (LTE)/ isolated G3 total bilirubin (TBL) that does not downgrade to G1 or less within 14 days of onset, isolated G4 LTE or TBL, elevated aspartate aminotransferase/alanine aminotransferase >3×upper limit of normal (ULN) and concurrent TBL >2×ULN without cholestasis or alternative explanations, any other toxicity judged as a DLT by Dose Escalation Committee.

    Measured: From Day 1 to 28 days after the first dose of study drugs

  3. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase

    Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.

    Measured: Day 1 through 65.7 weeks (maximum observed duration)

  4. Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase

    Number of participants with abnormal ECG parameters reported as TEAEs are reported.

    Measured: Day 1 through 65.7 weeks (maximum observed duration)

  5. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

    Measured: Day 1 through 65.7 weeks (maximum observed duration)

  6. Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase

    The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Secondary outcomes (23)
  1. Number of Participants With TEAEs and TESAEs in Dose Expansion Phase

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Measured: Day 1 through 172.1 weeks (maximum observed duration)

  2. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase

    Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.

    Measured: Day 1 through 172.1 weeks (maximum observed duration)

  3. Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase

    Number of participants with abnormal ECG parameters reported as TEAEs are reported.

    Measured: Day 1 through 172.1 weeks (maximum observed duration)

  4. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

    Measured: Day 1 through 172.1 weeks (maximum observed duration)

  5. Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase

    The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.

    Measured: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

  6. Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase

    The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for >=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.

    Measured: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

  7. Number of Participants With Overall Survival Events in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported.

    Measured: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  8. Overall Survival in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method.

    Measured: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  9. Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase

    Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  10. Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase

    The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  11. Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase

    The DoR is defined as the time from the first documentation of an OR until the first documentation of a PD or death due to any cause, whichever occurs first. The OR is defined as best overall response of confirmed CR or PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis < 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. The DoR is assessed using the Kaplan-Meier method.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  12. Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase

    The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for >=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  13. Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

    The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis <10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in >=50% of tumor cells.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  14. Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in >=50% of tumor cells. The number of participants with overall survival events (deaths) is reported.

    Measured: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  15. Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or <50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in >=50% of tumor cells.

    Measured: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  16. Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

    PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD:>=20% increase in SoD of TLs and an absolute increase of >= 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in >=50% of tumor cells. Number of participants with PFS events is reported.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  17. Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

    The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant receives subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in >=50% of tumor cells.

    Measured: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  18. Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab

    Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at >= 2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at >= 2 post-baseline assessments (with <16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.

    Measured: Day 1 through 172.1 weeks (Pre-dose on Cycle [C] 1 Day [D] 1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of oleclumab)

  19. Number of Participants With Positive ADA to Durvalumab

    Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at >= 2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at >= 2 post-baseline assessments (with <16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.

    Measured: Day 1 through 128 weeks (Pre-dose on C1D1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of durvalumab)

  20. Serum Concentrations of Oleclumab

    Serum concentrations of oleclumab are reported.

    Measured: Ten minutes (mins) (± 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1

  21. Serum Concentrations of Durvalumab

    Serum concentrations of durvalumab are reported.

    Measured: Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1

  22. Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)

    Plasma concentrations of gemcitabine and metabolite dFdU are reported.

    Measured: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

  23. Plasma Concentrations of Nab-paclitaxel

    Plasma concentrations of nab-paclitaxel are reported.

    Measured: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2018
  2. Study start21 Jun 2018
  3. Primary completion22 Jul 2022
  4. Study completion22 Jul 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
213 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03611556
Sponsor's protocol ID
D6070C00005
Other IDs
D6070C00005, 2018-001028-21, 2018
Status last verified
Sep 2023
First submitted
18 May 2018
Last updated
3 Oct 2023
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Oleclumab, Durvalumab and Gemcitabine in people with Carcinoma and Metastatic Pancreatic Adenocarcinoma, run by MedImmune LLC at 27 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 27 sites in United States, Australia, Spain, Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Oct 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase (time frame: Day 1 through 65.7 weeks (maximum observed duration)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2023; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in